224 related articles for article (PubMed ID: 27106898)
1. Cell Cycle Regulation and Melanoma.
Xu W; McArthur G
Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
[TBL] [Abstract][Full Text] [Related]
2. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
3. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
Barnaba N; LaRocque JR
Cell Cycle; 2021 Jun; 20(11):1041-1051. PubMed ID: 33966611
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle control as a promising target in melanoma.
Lee B; Sandhu S; McArthur G
Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
[TBL] [Abstract][Full Text] [Related]
5. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
7. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
[TBL] [Abstract][Full Text] [Related]
8. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
9. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
11. Getting under the skin: The role of CDK4/6 in melanomas.
Guo L; Qi J; Wang H; Jiang X; Liu Y
Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
13. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
15. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.
Eliades P; Miller DM; Miao B; Kumar R; Taylor M; Buch S; Srinivasa SP; Flaherty KT; Tsao H
Cancer Biol Ther; 2016 Jul; 17(7):778-84. PubMed ID: 26810603
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
VanArsdale T; Boshoff C; Arndt KT; Abraham RT
Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
[TBL] [Abstract][Full Text] [Related]
17. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
18. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
19. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
20. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]